Recurrent Glioma Clinical Trial
Official title:
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation
Study AG881-C-004 is a phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy of vorasidenib to placebo in participants with residual or recurrent Grade 2 glioma with an IDH1 or IDH2 mutation who have undergone surgery as their only treatment. Participants will be required to have central confirmation of IDH mutation status prior to randomization. Approximately 340 participants are planned to be randomized 1:1 to receive orally administered vorasidenib 40 mg QD or placebo.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03233204 -
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
| Recruiting |
NCT05045027 -
Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma
|
Early Phase 1 | |
| Not yet recruiting |
NCT04562077 -
Role of Surgery in Treatment of Recurrent Brian Glioma:Prognostic Factors and Outcome
|
||
| Active, not recruiting |
NCT05611645 -
Low-dose Bevacizumab With HSRT vs BVZ Alone for GBM at First Recurrence
|
Phase 2 | |
| Completed |
NCT04089449 -
A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas
|
Phase 1 | |
| Active, not recruiting |
NCT03213678 -
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
| Active, not recruiting |
NCT03698994 -
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
| Active, not recruiting |
NCT03213665 -
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
| Terminated |
NCT01324635 -
Panobinostat and Stereotactic Radiation Therapy in Treating Patients With Brain Tumors
|
Phase 1 | |
| Recruiting |
NCT05406700 -
Niraparib In Recurrent IDH 1/2 Gliomas
|
Early Phase 1 | |
| Recruiting |
NCT05660369 -
CARv3-TEAM-E T Cells in Glioblastoma
|
Phase 1 | |
| Recruiting |
NCT03796273 -
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
|
Early Phase 1 | |
| Terminated |
NCT05297864 -
PARP Inhibition for Gliomas (PI-4G or π4g)
|
Phase 2 | |
| Completed |
NCT01580969 -
Repeat Radiation, Minocycline and Bevacizumab in Patients With Recurrent Glioma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03155620 -
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)
|
Phase 2 | |
| Recruiting |
NCT04943718 -
Personalized Vaccine for Patients With Recurrent Malignant Glioma
|
Phase 1 | |
| Active, not recruiting |
NCT03212274 -
Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations
|
Phase 2 | |
| Recruiting |
NCT04740190 -
Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd
|
Phase 2 | |
| Recruiting |
NCT04216550 -
Prediction of Therapeutic Response of Apatinib in Recurrent Gliomas
|
||
| Recruiting |
NCT03411408 -
Accelerated Hypofractionated Intensity - Modulated Radiotherapy After Hyperbaric Oxygenation for Recurrent High Grade Glioma.
|
N/A |